Chapter 3. Immunoliposomes: A Targeted Delivery Tool for Cancer Treatment
- David T. Curiel M.D. and
- Joanne T. Douglas Ph.D.
Published Online: 31 MAR 2003
Copyright © 2002 John Wiley & Sons, Inc.
Vector Targeting for Therapeutic Gene Delivery
How to Cite
Pirollo, K. F., Xu, L. and Chang, E. H. (2003) Immunoliposomes: A Targeted Delivery Tool for Cancer Treatment, in Vector Targeting for Therapeutic Gene Delivery (eds D. T. Curiel and J. T. Douglas), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/0471234303.ch3
Division of Human Gene Therapy, Departments of Medicine, Pathology and Surgery, and the Gene Therapy Center, The University of Alabama at Birmingham, USA
- Published Online: 31 MAR 2003
- Published Print: 9 AUG 2002
Print ISBN: 9780471434795
Online ISBN: 9780471234302
- monoclonal antibody;
- gene therapy;
- tumor targeting;
- anti-transferrin receptor;
Within the last decade, we have seen a rapid expansion in the use of monoclonal antibodies as targeting molecules in medicine. However, the disadvantages associated with intact antibodies has limited their therapeutic usefulness. The development of small biologically active antibody fragments, such as the scFv molecules, has provided a way to circumvent some of these problems. This, coupled with the use of liposomes as drug and gene delivery vehicles, has broadened the potential of immunotherapy for cancer.
In this chapter we examine some of the factors influencing, and review some of the latest reports describing, the ability of antibody targeted immunoliposomal complexes to target both primary tumors and metastases as we work toward more effective therapeutic modalities.